NASDAQ:TTOO - T2 Biosystems Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.57 -0.10 (-3.75 %) (As of 03/19/2019 03:19 PM ET)Previous Close$2.67Today's Range$2.57 - $2.7152-Week Range$2.47 - $9.98Volume5,936 shsAverage Volume1.31 million shsMarket Capitalization$113.90 millionP/E Ratio-2.06Dividend YieldN/ABeta1.87 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications, as well as T2Candida panel for the detection of candida species in human whole blood specimens. In addition, it is developing T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2Lyme for the detection of various strains of Lyme disease-causing bacteria; and T2Plex, an integrated instrument for hemostasis applications. The company has collaboration agreement with Canon U.S. Life Sciences, Inc. to develop a novel diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC for the direct detection diagnostic test panel that adds additional bacteria species to the existing T2Bacteria product candidate and testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts. Receive TTOO News and Ratings via Email Sign-up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TTOO Previous Symbol CUSIPN/A CIK1492674 Webwww.t2biosystems.com Phone781-761-4646Debt Debt-to-Equity Ratio0.04 Current Ratio1.08 Quick Ratio1.03Price-To-Earnings Trailing P/E Ratio-2.06 Forward P/E Ratio-2.50 P/E GrowthN/A Sales & Book Value Annual Sales$10.50 million Price / Sales10.85 Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book9.88Profitability EPS (Most Recent Fiscal Year)($1.26) Net Income$-51,150,000.00 Net Margins-487.17% Return on Equity-336.09% Return on Assets-75.89%Miscellaneous EmployeesN/A Outstanding Shares44,320,000Market Cap$113.90 million Next Earnings Date5/14/2019 (Estimated) OptionableOptionable T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions What is T2 Biosystems' stock symbol? T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO." How were T2 Biosystems' earnings last quarter? T2 Biosystems Inc (NASDAQ:TTOO) announced its quarterly earnings results on Thursday, March, 7th. The medical equipment provider reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.04. The medical equipment provider had revenue of $1.79 million for the quarter, compared to analysts' expectations of $2.52 million. T2 Biosystems had a negative net margin of 487.17% and a negative return on equity of 336.09%. View T2 Biosystems' Earnings History. When is T2 Biosystems' next earnings date? T2 Biosystems is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for T2 Biosystems. What guidance has T2 Biosystems issued on next quarter's earnings? T2 Biosystems updated its FY 2019 earnings guidance on Thursday, March, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $21-21 million, compared to the consensus revenue estimate of $21.77 million.T2 Biosystems also updated its Q1 2019 guidance to EPS. What price target have analysts set for TTOO? 6 brokers have issued 1-year price targets for T2 Biosystems' shares. Their predictions range from $5.00 to $11.00. On average, they expect T2 Biosystems' stock price to reach $9.25 in the next twelve months. This suggests a possible upside of 259.9% from the stock's current price. View Analyst Price Targets for T2 Biosystems. What is the consensus analysts' recommendation for T2 Biosystems? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for T2 Biosystems. What are Wall Street analysts saying about T2 Biosystems stock? Here are some recent quotes from research analysts about T2 Biosystems stock: 1. According to Zacks Investment Research, "T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts. " (3/13/2019) 2. HC Wainwright analysts commented, "We have slightly lowered our 2019 revenue projection to $21M from $22M, and increased the estimates for overall operating expenses based on recent trends. Our current estimated market value of the firm has decreased to $557M from $675M. Assuming approximately 50M shares outstanding at the end of 1Q20, this translates to a per share value of approximately $11. Therefore, we reiterate our Buy rating, while reducing the 12-month price target to $11 from $14 per share." (3/8/2019) 3. Canaccord Genuity analysts commented, "We’d like to provide our view and counter the key points made in the report: Point 1 – News of T2’s recent Breakthrough Device designation by the FDA isn’t an acknowledgement of the device’s effectiveness or clinical value proposition, or that the device has value, only that it diagnoses life-threatening disease. Our response – This is true, but it’s still a positive. T2 just started its dialogue with the FDA on its T2Resistance panel, thus FDA has not reviewed data from T2. We believe that breakthrough device designation will (1) add more resources by the FDA on this device and (2) likely provide a speedier review process and ultimately FDA approval." (3/5/2019) 4. Cantor Fitzgerald analysts commented, ": We are initiating coverage of T2 Biosystems (TTOO) with an Overweight rating and a 12-month price target of $11. We think T2’s direct-from-whole-blood species-specific technology has the potential to change the standard of care for sepsis diagnostics. T2’s diagnostic panels for bacterial and fungal infections deliver a species-specific result in 3-5 hours, compared to 2-5 days for the current standard of care. We foresee favorable emergency department economics as a gateway for hospitals to adopt T2’s technology before a broader rollout to the ICU and sepsis testing more broadly." (9/20/2018) Has T2 Biosystems been receiving favorable news coverage? News headlines about TTOO stock have trended neutral on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. T2 Biosystems earned a coverage optimism score of 0.2 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of T2 Biosystems' key competitors? Some companies that are related to T2 Biosystems include SI-Bone (SIBN), Anika Therapeutics (ANIK), Accuray (ARAY), MiMedx Group (MDXG), GenMark Diagnostics (GNMK), Pulse Biosciences (PLSE), Inovio Pharmaceuticals (INO), Vapotherm (VAPO), Utah Medical Products (UTMD), Neuronetics (STIM), Iradimed (IRMD), Westaim (WEDXF), Liquidia Technologies (LQDA), SeaSpine (SPNE) and Apyx Medical (APYX). What other stocks do shareholders of T2 Biosystems own? Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Progenics Pharmaceuticals (PGNX), Verastem (VSTM), Synergy Pharmaceuticals (SGYP), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Tetraphase Pharmaceuticals (TTPH) and Alibaba Group (BABA). Who are T2 Biosystems' key executives? T2 Biosystems' management team includes the folowing people: Mr. John P. McDonough, CEO, Pres & Director (Age 59)Prof. Michael J. Cima, Co-Founder & Director (Age 59)Dr. Thomas J. Lowery Jr., Chief Scientific Officer (Age 40)Dr. Tyler E. Jacks, Co-Founder (Age 58)Mr. Lee Josephson, Co-Founder & Member of Scientific Advisory Board Who are T2 Biosystems' major shareholders? T2 Biosystems' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.67%), Geode Capital Management LLC (0.85%), Geode Capital Management LLC (0.85%), Essex Investment Management Co. LLC (0.79%), Bell Rock Capital LLC (0.73%) and ClariVest Asset Management LLC (0.43%). Company insiders that own T2 Biosystems stock include Darlene M Deptula-Hicks, David B Elsbree, Joanne Spadoro, John Mcdonough, Michael Terrence Gibbs, Stanley Lapidus and Thomas J Lowery. View Institutional Ownership Trends for T2 Biosystems. Which major investors are selling T2 Biosystems stock? TTOO stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Emerald Mutual Fund Advisers Trust and Barclays PLC. Company insiders that have sold T2 Biosystems company stock in the last year include John Mcdonough, Michael Terrence Gibbs, Stanley Lapidus and Thomas J Lowery. View Insider Buying and Selling for T2 Biosystems. Which major investors are buying T2 Biosystems stock? TTOO stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., BlackRock Inc., ClariVest Asset Management LLC, Gagnon Securities LLC, Algert Global LLC, Virtu Financial LLC, Pathlight Investors LLC and Bell Rock Capital LLC. Company insiders that have bought T2 Biosystems stock in the last two years include Darlene M Deptula-Hicks, David B Elsbree, Joanne Spadoro and Michael Terrence Gibbs. View Insider Buying and Selling for T2 Biosystems. How do I buy shares of T2 Biosystems? Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is T2 Biosystems' stock price today? One share of TTOO stock can currently be purchased for approximately $2.57. How big of a company is T2 Biosystems? T2 Biosystems has a market capitalization of $113.90 million and generates $10.50 million in revenue each year. The medical equipment provider earns $-51,150,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. What is T2 Biosystems' official website? The official website for T2 Biosystems is http://www.t2biosystems.com. How can I contact T2 Biosystems? T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at 781-761-4646 or via email at [email protected] MarketBeat Community Rating for T2 Biosystems (NASDAQ TTOO)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 269 (Vote Outperform)Underperform Votes: 227 (Vote Underperform)Total Votes: 496MarketBeat's community ratings are surveys of what our community members think about T2 Biosystems and other stocks. Vote "Outperform" if you believe TTOO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTOO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/19/2019 by MarketBeat.com StaffFeatured Article: Why is the Consumer Price Index (CPI) important?